{"doi":"10.1016/j.lungcan.2018.12.010","title":"Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M","abstract":null,"journal":"Lung Cancer","year":2019,"id":634841,"datarank":0.5495342469194471,"base_score":3.6635616461296463,"endowment":3.6635616461296463,"self_citation_contribution":0.5495342469194471,"citation_network_contribution":0.0,"self_endowment_contribution":0.5495342469194471,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":38,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1402787,"name":"Xuefei Li","orcid":"0000-0001-9281-4383","position":1,"is_corresponding":false},{"id":114635,"name":"Chao Zhao","orcid":"0000-0003-1739-1151","position":2,"is_corresponding":false},{"id":883227,"name":"Tao Jiang","orcid":"0000-0002-8529-4487","position":3,"is_corresponding":false},{"id":1646720,"name":"Yijun Jia","orcid":null,"position":4,"is_corresponding":false},{"id":1646721,"name":"Jinpeng Shi","orcid":null,"position":5,"is_corresponding":false},{"id":52500,"name":"Yayi He","orcid":"0000-0002-2878-8595","position":6,"is_corresponding":false},{"id":1252543,"name":"Jiayu Li","orcid":"0000-0002-6774-4325","position":7,"is_corresponding":false},{"id":78953,"name":"Fei Zhou","orcid":"0000-0002-9871-4882","position":8,"is_corresponding":false},{"id":587843,"name":"Guanghui Gao","orcid":"0000-0003-2947-2311","position":9,"is_corresponding":false},{"id":717111,"name":"Wei Li","orcid":"0000-0002-7530-4872","position":10,"is_corresponding":false},{"id":1544834,"name":"Xiaoxia Chen","orcid":null,"position":11,"is_corresponding":false},{"id":1646722,"name":"Chunxia Su","orcid":null,"position":12,"is_corresponding":false},{"id":851104,"name":"Shengxiang Ren","orcid":"0000-0001-8767-9850","position":13,"is_corresponding":false},{"id":1015049,"name":"Caicun Zhou","orcid":"0000-0002-2246-5541","position":14,"is_corresponding":false},{"id":1331904,"name":"Sha Zhao","orcid":"0000-0003-4628-5198","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M","abstract":"<h4>Background</h4>Osimertinib demonstrates superior efficacy in patients with non-small cell lung cancer (NSCLC) who acquired EGFR T790M mutation as resistant mechanism to upfront EGFR tyrosine kinase inhibitors (TKIs). Not all the T790M-positive tumors are homogeneously sensitive to osimertinib, however, and the duration of response often varies. Previous studies suggest that loss of T790 M at osimertinib resistance is correlated with shortened survival benefit of osimertinib. The aim of this study is to investigate the prevalence of T790 M loss after progression to osimertinib in Chinese patients with NSCLC harboring EGFR T790 M mutation and to compare their clinical outcomes and characteristics when stratified by T790 M mutational status at osimertinib resistance.<h4>Patients and methods</h4>All patients with a secondary T790 M mutation after progression to prior-line EGFR TKIs and received single-agent osimertinib were reviewed. The patients who were reassessed for T790 M mutation post-osimertinib resistance were included in final analysis. Detailed clinicopathologic characteristics and response data were collected.<h4>Results</h4>Of the patients with confirmed T790 M mutation as acquired resistance to early-generation EGFR TKIs and subsequently received single-agent osimertinib, 84 patients experienced clinical progression after osimertinib treatment and were eligible for analysis. Among them, 31 patients underwent repeated T790 M mutation testing on osimertinib resistance. Sixteen patients had maintained T790 M mutation, whereas 15 patients lost T790 M at resistance. Loss of T790 M at resistance was remarkably correlated with shorter duration of response to osimertinib (P = 0.0005). Furthermore, the overall survival after osimertinib treatment was also decreased in T790M-loss group (P=0.021). The objective response rates were comparable between T790M-maintain and T790M-loss group (31.3% and 26.7%, respectively). In multivariate analysis, loss of T790M remained statistically associated with early progression to osimertinib.<h4>Conclusion</h4>Loss of T790 M mutation at resistance was correlated with early progression and overall survival in response to osimertinib treatment in Chinese patients with NSCLC harboring acquired T790 M mutation.","is_dataset_classified":null,"base_score":3.6635616461296463,"endowment":3.6635616461296463,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"30642450","pmcid":null,"openalex_id":"https://openalex.org/W2904882123","authors":[],"funders":[{"funder_name":"National Natural Science Foundation of China","grant_id":"81672286","title":null},{"funder_name":"Innovation Program for Basic Research of the Science and Technology Commission Shanghai Municipality","grant_id":"16JC1405900","title":null},{"funder_name":"Shanghai Hygiene and Health Committee’s Key Discipline Project of Respiratory Diseases","grant_id":"2017ZZ02012","title":null},{"funder_name":"National Key Research and Development Projects of China","grant_id":"2016YFC0902300","title":null}],"total_grants":4,"fwci":3.3528,"citation_percentile":0.93445021,"influential_citations":0,"citation_trend":[{"year":2019,"count":2},{"year":2020,"count":7},{"year":2021,"count":12},{"year":2022,"count":8},{"year":2023,"count":2},{"year":2024,"count":6},{"year":2025,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0169500218306962?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0169500218306962?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.lungcan.2018.12.010","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/30642450","host_type":"repository"}],"fields_of_study":["Lung Cancer Treatments and Mutations","Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","Lung Cancer Diagnosis and Treatment"],"mesh_terms":["Acrylamides","Aged","Aged, 80 and over","Aniline Compounds","Biopsy","Carcinoma, Non-Small-Cell Lung","Female","Humans","Indoles","Lung Neoplasms","Male","Middle Aged","Mutation","Neoplasm Metastasis","Neoplasm Staging","Prognosis","Pyrimidines","Biomarkers, Tumor","Disease Progression","Protein Kinase Inhibitors","ErbB Receptors"],"keywords":["Osimertinib","T790M","Medicine","Mutation","Oncology","Internal medicine","Cancer research","Genetics","Epidermal growth factor receptor","Cancer","Gene","Biology","Gefitinib","Non-small cell lung cancer","Early Progression","Loss Of T790m Mutation"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T14:14:54.533380Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}